Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18125956 | 0.98 | CHRM1 (0.50) | CHRM1L3MBTL3L3MBTL1HRH3TP53 | |
| SCHEMBL31664986 | 0.94 | CHRM1 (0.46) | CHRM1L3MBTL3L3MBTL1HRH3TP53 | |
| SCHEMBL20744151 | 0.90 | L3MBTL3 (0.49) | CHRM1L3MBTL3L3MBTL1HRH3SIGMAR1 | |
| SCHEMBL20744086 | 0.89 | L3MBTL3 (0.47) | CHRM1L3MBTL3L3MBTL1POLBSIGMAR1 | |
| SCHEMBL20744085 | 0.89 | L3MBTL3 (0.47) | CHRM1L3MBTL3L3MBTL1POLBSIGMAR1 | |
| SCHEMBL3401436 | 0.88 | L3MBTL3 (0.57) | L3MBTL3L3MBTL1 | |
| SCHEMBL29676554 | 0.88 | L3MBTL3 (0.57) | L3MBTL3L3MBTL1 | |
| SCHEMBL3400330 | 0.88 | L3MBTL3 (0.57) | L3MBTL3L3MBTL1 | |
| SCHEMBL20744036 | 0.86 | CHRNA7 (0.50) | CHRM1L3MBTL3L3MBTL1HRH3POLB | |
| SCHEMBL28414360 | 0.86 | CHRNA7 (0.50) | CHRM1L3MBTL3L3MBTL1HRH3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217226-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-07-22 | — | — | EP | disclosed |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-02-21 | — | — | US | disclosed |
| EP-2217226-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2009-12-10 | — | — | US | disclosed |
| WO-2009061879-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DPEP1, DHPS | CHRM1 4857/4885L3MBTL3 3001/4885L3MBTL1 2039/4885 |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DHPS, PADI3 | CHRM1 4835/4885L3MBTL3 1889/4885L3MBTL1 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.